Recognizing the significance of Charcot-Marie-Tooth disease and the need for robust funding of the National Institute of Neurological Disorders and Stroke at the National Institutes of Health.
Summary
H. Res. 1079 is a House resolution recognizing Charcot-Marie-Tooth disease (CMT) as a significant neurological disorder and urging robust federal research funding for it. The resolution describes CMT as a hereditary disease that damages peripheral nerves, affects muscle control, and impacts an estimated 126,000 people in the United States and 2.6 million worldwide. It also notes that the specific gene responsible for CMT has not yet been identified and that there are multiple forms of the disease, including CMT4B3.
The resolution does not create a new program or mandate direct spending. Instead, it expresses the sense of the House that the National Institute of Neurological Disorders and Stroke at the National Institutes of Health should continue to receive strong support for CMT research and for research into other rare diseases with no cure. It also highlights that federal funding for CMT research was lower in 2022 than in 2021, using that as a basis for calling for increased investment.
Because this is a resolution, its legal effect is limited: it does not amend state law or federal statutes, and it does not impose regulatory requirements on states, agencies, or private parties. Its practical impact would be symbolic and advocacy-oriented, aimed at influencing federal research priorities and appropriations decisions at NIH/NINDS.
The overall sentiment reflected in the bill text is strongly supportive of patients, families, and biomedical research. The resolution frames CMT as an under-recognized rare disease deserving greater attention and funding, and there is no recorded opposition, vote, or committee debate in the provided materials. The main point of emphasis is the need for more research funding, especially given the lack of a known cure and the absence of an identified causative gene for all cases.
Impact
This resolution has no direct effect on state laws or statutory obligations. It is a nonbinding House expression of support for increased federal research funding at NIH/NINDS, so any practical impact would be indirect through federal appropriations priorities and public awareness rather than legal changes for states, agencies, or private entities.
Sentiment
The available materials show a uniformly positive and supportive tone toward the resolution. The sponsors present CMT as a serious rare disease affecting many people and argue that federal research funding should be strengthened. No votes, amendments, or committee remarks are provided, so there is no evidence of recorded opposition or divided sentiment in the supplied record.
Contention
No specific contention is shown in the provided text or legislative history. The only implicit policy issue is whether federal research funding for CMT and other rare diseases should be increased, especially in light of the statement that CMT research funding declined from 2021 to 2022. Because the resolution is nonbinding and there are no transcripts or votes, no named opponents or competing arguments are available.
Urging Congress to ensure strong annual federal funding for the National Institutes of Health and to increase investment in cutting-edge medical research through grants from the NIH to research institutions.
A resolution expressing the sense of the Senate that the operations of the National Institutes of Health should not experience any interruption, delay, or funding disruption in violation of the law and that the workforce of the National Institutes of Health is essential to sustaining medical progress.
Proposing a constitutional amendment providing for the establishment of the Mental Health and Brain Research Institute of Texas and the Mental Health and Brain Institute Research Fund to provide funding for scientific research of mental health issues and human brain diseases and disorders.
Requesting The University Of Hawaii To Explore The Feasibility Of Establishing An Alzheimer's Disease Research Center And Identify The Requirements For Receiving Federal Funding From The National Institute On Aging For Alzheimer's Disease Research.